
The departments of Health and Human Services and Defense have agreed to purchase the first 300,000 doses of the investigational antibody drug bamlanivimab, also known as LY-CoV555, which state and territorial health departments will distribute to health care facilities for use in COVID-19 outpatients if the Food and Drug Administration authorizes the drug.